Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga - Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Department of Traditional Healer, Faculty of Vocations, Universitas Airlangga, Surabaya, Indonesia.
J Acupunct Meridian Stud. 2021 Feb 28;14(1):4-12. doi: 10.51507/j.jams.2021.14.1.4.
Pain is a major complaint in cancer patients and a global problem that requires medical attention, including pain in cervical cancer. Although pharmacotherapy has been used for the treatment of cancer pain, there are still around 40% cannot be treated only with pharmacotherapy.
To determine the effects of electroacupuncture (EA) on pain in stage III cervical cancer patients.
Twenty-eight stage III cervical cancer patients were divided into two groups (14 treatments and 14 controls) with randomized control trial design. The treatment group received EA with a frequency of 2/20-25 Hz at points of ST36, SP6, LI4 and LR3 for 30 minutes, while the control group did not receive EA. Both groups were given paracetamol and codeine at the same dose. Assessment was carried out by measuring pain scale (VAS), plasma β-endorphin levels, and quality of life/QoL (EORTC QLQ-C30) before and after therapy.
The average reduction in VAS in the treatment group (2.71 ± 1.14) compared to the control group (0.71 ± 1.33; < 0.001), average increase in plasma β-endorphin levels in the treatment group (88.57 ± 52.46 pg/ml) compared to the control group (12.86 ± 56.76 pg/ml; = 0.001), and in QoL, there were significant differences in symptom improvement between the treatment and control groups in the domain of fatigue, pain, insomnia and overall QoL ( < 0.05).
Medical therapy combined with EA decreased pain scale, increased plasma β-endorphin levels, and improved the QoL for stage III cervical cancer patients.
疼痛是癌症患者的主要主诉,也是一个全球性问题,需要医学关注,包括宫颈癌疼痛。虽然药物治疗已被用于治疗癌症疼痛,但仍有大约 40%的患者不能仅通过药物治疗得到缓解。
评估电针对Ⅲ期宫颈癌患者疼痛的影响。
采用随机对照试验设计,将 28 例Ⅲ期宫颈癌患者分为两组(治疗组 14 例,对照组 14 例)。治疗组接受 ST36、SP6、LI4 和 LR3 穴位的 2/20-25 Hz 电针治疗,每次 30 分钟,对照组不接受电针治疗。两组均给予相同剂量的扑热息痛和可待因。治疗前后通过疼痛量表(VAS)、血浆β-内啡肽水平和生活质量(EORTC QLQ-C30)进行评估。
与对照组(0.71 ± 1.33)相比,治疗组 VAS 平均降低(2.71 ± 1.14)( < 0.001),治疗组血浆β-内啡肽水平平均升高(88.57 ± 52.46 pg/ml)与对照组(12.86 ± 56.76 pg/ml)相比( < 0.001),在生活质量方面,治疗组在疲劳、疼痛、失眠和整体生活质量方面的症状改善与对照组有显著差异( < 0.05)。
药物治疗联合电针可降低疼痛评分,增加血浆β-内啡肽水平,改善Ⅲ期宫颈癌患者的生活质量。